About Us

Overview
Management
Board of Directors

Partners
Dynavax Europe

About Us :: Overview

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. Our lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. HEPLISAV-B combines our proprietary TLR 9 agonist adjuvant and hepatitis B surface antigen to elicit a potent immune response after just two doses. We are conducting a Phase 3 study of HEPLISAV-B compared with Engerix-B® in adults 18-70 years of age in order to provide a sufficiently-sized safety database for the FDA to complete its review of Dynavax's biologics license application.

Our clinical-stage product candidates include:

We have programs partnered with pharmaceutical companies, including AstraZeneca and GlaxoSmithKline.

Our European subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV.  With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.